Hoth rises as preclinical data shows fatty liver drug outperforms semaglutide
Brief: Hoth Therapeutics (Hoth) Reports Positive Ht-Va Crada Data Gdnf Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene And Activates Fat-Burning Pathways, Outperforming Semaglutide
Brief: Hoth Therapeutics Announces Closing Of $2 Million Registered Direct Offering
NASDAQ RESUMED AT 01:59 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:54 PM
Brief: Hoth Therapeutics Announces Issuance Of Chinese Patent For Cancer Cell-Targeting Technology
U.S. STOCKS ON THE MOVE-Dollar General, software stocks, Sable Offshore
U.S. STOCKS ON THE MOVE-FedEx, Estee Lauder, Janus Henderson
U.S. STOCKS ON THE MOVE-DexCom, Ocugen, Estee Lauder
Hoth Therapeutics rises as skin treatment shows promise in cancer patients
Brief: Hoth Therapeutics Reports Positive Ht-001 Pk, Safety, And Clinical Activity Data In Cancer Patients With Egfr Therapy
U.S. STOCKS ON THE MOVE-SSR Mining, Bath & Body Works, CoreWeave
Hoth Therapeutics rises as AI used to speed rare cancer drug development
Brief: Hoth Therapeutics Deploys Openai API To Advance Development Of Orphan Ht-Kit Oncology Program
Brief: Hoth Therapeutics Accelerates HT-001 Trial Enrollment With New Clinical Site As Patient Demand Increases
Brief: Hoth Therapeutics Receives U.S. Notice Of Allowance For Novel Exon-Skipping Therapy Targeting Allergic Diseases
Hoth Therapeutics rises as early obesity‑drug data in mice shows promise
Brief: Hoth Therapeutics Announces Groundbreaking Positive Results Hoth's Ht-Va Gdnf Surpasses Semaglutide In Weight Loss
Brief: Hoth Therapeutics Delivers 100% Clinical Response With ~50% Reduction In Disease Severity In Open-Label PK Cohort Of EGFR-Treated Cancer Patients